Investigational drug · Phase 2
VEL-101
Also called: Pegrizeprument, FR104
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Transplantation, Kidney.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "VEL-101"
First trial start
2026
Aug 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VEL-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Transplantation, Kidney
Approved drugs for the same conditions: Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "VEL-101" as an intervention, largest first.
- VEL-101 to Prevent Rejection After Kidney TransplantationPivotal-lookingRecruiting
Asahi Kasei Therapeutics, Inc.Industry
NCT07290777 · 120 participants (planned) · Start Aug 18, 2026 · Primary completion Oct 2028
Drug: Tacrolimus (TAC); VEL-101 · For: Transplantation, Kidney
Sites: Dallas, Texas
Asahi Kasei Therapeutics, Inc.Industry
NCT05238493 · 60 participants · Start Apr 26, 2022 · Primary completion Jan 3, 2023
Drug: VEL-101; Placebo · For: Healthy Volunteers
Sites: Cincinnati, Ohio
Newest research
PubMed records naming it or its code names, newest first.
- Safety, Pharmacokinetics, and Pharmacodynamics of Fixed-dose, Subcutaneous, and Intravenous Administration of VEL-101, an Anti-CD28 PEGylated Monoclonal Antibody Fragment, in Healthy Participants: A Randomized, Double-blind, Placebo-controlled, Dose Escalation, Phase 1 Study.
Tremblay S, Abaigar A, Allton P, et al. · Transplantation 2026
- Overcoming the undruggable barrier: Structure-guided discovery of a potent small molecule CD28 antagonist with translational potential.
Upadhyay S, Nada H, Cho S, et al. · Biomed Pharmacother 2026
- Surveillance of West Nile virus infections in humans and animals in Europe, monthly report - data submitted up to 3 December 2025.
· EFSA J 2025
- Structure-based virtual screening identifies potent CD28 inhibitors that suppress T cell co-stimulation in cellular and mucosal models.
Upadhyay S, Talagayev V, Cho S, et al. · Eur J Med Chem 2025
- Surveillance of West Nile virus infections in humans and animals in Europe, monthly report - data submitted up to 5 November 2025.
· EFSA J 2025
- Structure-Guided Optimization and Functional Characterization of Small Molecule Antagonists Targeting CD28 Costimulation.
Upadhyay S, Nada H, Cho S, et al. · bioRxiv 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.